- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01247272
90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions
January 24, 2011 updated by: Teva Pharmaceuticals USA
A Relative Bioavailability Study of 90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions
This study compared the relative bioavailability (rate and extent of absorption) of 90 mg Fluoxetine Hydrochloride Capsules by Teva Pharmaceuticals, USA with that of 90 mg PROZAC WEEKLY® Capsules by Eli Lilly and Company following a single oral dose (1 x 90 mg) in healthy adult volunteers under fasting conditions.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Dakota
-
Fargo, North Dakota, United States, 58102
- PRACS Institute, Ltd.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Screening Demographics: All volunteers selected for this study will be healthy men and women 18 years of age or older at the time of dosing. The weight range will not exceed + 15% for height and body frame as per Desirable Weights for Men - 1983 Metropolitan Height and Weight Table or Desirable Weights for Women - 1983 Metropolitan Height and Weight Table.
- Screening Procedures: Each volunteer will complete the screening process within 28 days prior to Period I dosing. Consent documents for both the screening evaluation and HIV antibody determination will be reviewed, discussed, and signed by each potential participant before full implementation of screening procedures.
If female and:
- Of childbearing potential, is practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), or
- Is postmenopausal for at least 1 year, or
- Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).
Exclusion Criteria:
- Volunteers with a recent history of drug or alcohol addiction or abuse.
- Volunteers with the presence of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (as determined by the clinical investigators).
- Volunteers whose clinical laboratory test values are outside the acceptable reference range and when confirmed on re-examination are deemed to be clinically significant.
- Volunteers demonstrating a positive hepatitis B surface antigen screen or a reactive HIV antibody screen.
- Volunteers demonstrating a positive drug abuse screen when screened for this study.
- Female volunteers demonstrating a positive pregnancy screen.
- Female volunteers who are currently breastfeeding.
- Volunteers with a history of allergic response(s) to fluoxetine or related drugs.
- Volunteers with a history of clinically significant allergies including drug allergies.
- Volunteers with a clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the clinical investigators).
- Volunteers who currently use tobacco products.
- Volunteers who have taken any drug known to induce or inhibit hepatic drug metabolism in the 30 days prior to Period I dosing.
- Volunteers who report donating greater than 150 mL of blood within 30 days prior to Period I dosing. All subjects will be advised not to donate blood for 4 weeks after completing the study.
- Volunteers who have donated plasma within 14 days prior to Period I dosing. All subjects will be advised not to donate plasma for 4 weeks after completing the study.
- Volunteers who report receiving any investigational drug within 30 days prior to Period I dosing.
- Volunteers who report taking any systemic prescription medication in the 14 days prior to Period I dosing.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Reference Listed Drug
90 mg PROZAC WEEKLY® Capsules (Eli Lilly)
|
90 mg Capsules
Other Names:
|
Experimental: Investigational Test Product
90 mg Fluoxetine Hydrochloride Capsules (Teva)
|
90 mg Capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax of Fluoxetine.
Time Frame: Blood samples collected over a 25 day period.
|
Bioequivalence based on Fluoxetine Cmax (maximum observed concentration of drug substance in plasma).
|
Blood samples collected over a 25 day period.
|
AUC0-t of Fluoxetine.
Time Frame: Blood samples collected over a 25 day period.
|
Bioequivalence based on Fluoxetine AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).
|
Blood samples collected over a 25 day period.
|
AUC0-inf of Fluoxetine.
Time Frame: Blood samples collected over a 25 day period.
|
Bioequivalence based on Fluoxetine AUC0-inf (area under the concentration-time curve from time zero to infinity).
|
Blood samples collected over a 25 day period.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax of Norfluoxetine.
Time Frame: Blood samples collected over a 25 day period.
|
Informational comparison of Cmax values for the metabolite Norfluoxetine.
|
Blood samples collected over a 25 day period.
|
AUC0-t of Norfluoxetine.
Time Frame: Blood samples collected over a 25 day period.
|
Informational comparison of AUC0-t values for the metabolite Norfluoxetine.
|
Blood samples collected over a 25 day period.
|
AUC0-inf of Norfluoxetine.
Time Frame: Blood samples collected over a 25 day period.
|
Bioequivalence based on Norfluoxetine AUC0-inf (area under the concentration-time curve from time zero to infinity).
|
Blood samples collected over a 25 day period.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2001
Primary Completion (Actual)
July 1, 2001
Study Completion (Actual)
July 1, 2001
Study Registration Dates
First Submitted
November 22, 2010
First Submitted That Met QC Criteria
November 22, 2010
First Posted (Estimate)
November 24, 2010
Study Record Updates
Last Update Posted (Estimate)
February 21, 2011
Last Update Submitted That Met QC Criteria
January 24, 2011
Last Verified
January 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP2D6 Inhibitors
- Fluoxetine
Other Study ID Numbers
- R01-140
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on PROZAC WEEKLY®
-
Bezmialem Vakif UniversityUnknownIntrauterine Growth Restriction | Fetal SurveillanceTurkey
-
University of CopenhagenCompletedGastric Cancer | Esophageal Cancer | Uterine CancerDenmark
-
University Hospital, BordeauxRecruitingSubstance-Related Disorders | Addictive BehaviorFrance
-
University of Wisconsin, MadisonNational Institute of Mental Health (NIMH); University of MichiganCompletedBipolar DisorderUnited States
-
Palo Alto Veterans Institute for ResearchNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingHemodialysis | Kidney Failure, ChronicUnited States
-
Carilion ClinicVirginia Polytechnic Institute and State UniversityCompletedQuality of Life | Self Efficacy | Behavior, Health | Cancer of EndometriumUnited States
-
VA Office of Research and DevelopmentRecruitingChronic Kidney Disease (CKD) Stage 5 | Kidney Dysfunction Requiring Dialysis (KDRD) | Dialysis DependencyUnited States
-
The University of Hong KongRecruiting
-
Northside Clinic, AustraliaTerminated
-
Seelos Therapeutics, Inc.WithdrawnAlzheimer's DiseaseAustralia